Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5960582 | 0.98 | — | — | |
| SCHEMBL6446235 | 0.96 | PSMB5 (0.33) | TYMP | |
| SCHEMBL13858383 | 0.94 | PSMB5 (0.32) | TYMP | |
| SCHEMBL7402470 | 0.94 | PSMB5 (0.32) | TYMP | |
| SCHEMBL3082501 | 0.94 | PSMB5 (0.32) | TYMP | |
| SCHEMBL4796621 | 0.94 | PSMB5 (0.32) | TYMP | |
| SCHEMBL3796622 | 0.94 | PSMB5 (0.32) | TYMP | |
| SCHEMBL604265 | 0.93 | TYMP (0.31) | TYMP | |
| SCHEMBL5808874 | 0.91 | ALDH1A1 (0.35) | TYMP | |
| SCHEMBL9815606 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105777558-A | Compound, organic light-emitting device including the same, and flat-panel display | 三星显示有限公司 | 2016-07-20 | — | — | CN | claimed |
| US-6080763-A | INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES, E.G., TUMOR NECROSIS FACTOR AND INTERLEUKIN-1; USEFUL TO TREAT CHRONIC INFLAMMATORY DISEASE; AUTOIMMUNE DISEASES, E.G. RHEUMATOID ARTHRITIS, OSTEOPOROSIS; PYRAZOLYLUREAS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-06-27 | — | — | US | claimed |
| US-20240059681-A1 | NITRILE DERIVATIVE THAT ACTS AS INHIBITOR OF DIPEPTIDYL PEPTIDASE 1 AND USE THEREOF | HAISCO PHARMACEUTICALS PTE. LTD. (SG) | 2024-02-22 | — | — | US | disclosed |
| WO-2021059017-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-01 | — | — | WO | disclosed |
| CN-105431149-B | Neuroprotective multifunctional antioxidants and their monofunctional analogs | 彼得·F·卡罗 | 2019-06-11 | — | — | CN | disclosed |
| EP-2956140-B1 | NEUROPROTECTIVE MULTIFUNCTIONAL ANTIOXIDANTS AND THEIR MONOFUNCTIONAL ANALOGS | KADOR PETER F (US) | 2018-07-11 | — | — | EP | disclosed |
| US-9775829-B2 | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160374990-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2016-12-29 | — | — | US | disclosed |
| EP-3066094-A1 | PYRAZOLE FOR THE TREATMENT AUTOIMMUNE DISORDERS | Takeda Pharmaceutical Company Limited (JP) | 2016-09-14 | — | — | EP | disclosed |
| CN-105777558-A | Compound, organic light-emitting device including the same, and flat-panel display | 三星显示有限公司 | 2016-07-20 | — | — | CN | disclosed |
| CN-105732562-A | COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING THE COMPOUND, AND PANEL DISLAY DEVICE COMPRISING THE ORGANIC LIGHT-EMITTING DEVICE | 三星显示有限公司 | 2016-07-06 | — | — | CN | disclosed |
| US-20060135508-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2006-06-22 | — | — | US | disclosed |
| JP-2004534002-A | — | — | 2004-11-11 | — | — | JP | disclosed |
| US-20030225111-A1 | Therapy | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | disclosed |
| EP-0251164-B1 | NEW CHIRAL PHOSPHINOPYRROLIDINE COMPOUNDS AND THEIR USE FOR ASYMETRIC SYNTHESIS OF OPTICALLY ACTIVE COMPOUNDS | Achiwa, Kazuo (JP) | 1992-12-16 | — | — | EP | disclosed |
| US-5075384-A | Air-drying, curable protective coatings comprising an allyl alcohol-styrene copolymer carbamylated by an unsaturated isocyanate, an acrylic monomer and an allyl monomer; gloss; toughness | MONSANTO (US) | 1991-12-24 | — | — | US | disclosed |
| US-5030696-A | Air- or heat-curable protective coatings of unsaturated isocyanate-modified styrene-allyl alcohol copolymer, an acrylic compound and an allyl compound; furniture; toughness | MONSANTO COMPANY (US) | 1991-07-09 | — | — | US | disclosed |
| US-5026771-A | Coating compositions containing ethylenically unsaturated carbamates | MONSANTO COMPANY (US) | 1991-06-25 | — | — | US | disclosed |
| EP-0251164-A2 | New chiral phosphinopyrrolidine compounds and their use for asymetric synthesis of optically active compounds | Achiwa, Kazuo (JP) | 1988-01-07 | — | — | EP | disclosed |
| US-4216232-A | Pharmaceutical compositions | BEECHAM GROUP LIMITED (GB) | 1980-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225111-A1 | Therapy | VEGFA, AQP1, FLT1 | TYMP 1739/4885 |
| US-20240059681-A1 | NITRILE DERIVATIVE THAT ACTS AS INHIBITOR OF DIPEPTIDYL PEPTIDASE 1 AND USE THEREOF | DPP4, DPP3, DPP9 | TYMP 4172/4885 |
| US-20160374990-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR2C | TYMP 4108/4885 |
| US-20060135508-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K15, MAP3K5, MAP3K19 | TYMP 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.